Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease.
1. A method of treatment for Alzheimer's disease, comprising the steps of:
a. selecting a human patient having, or at risk of Alzheimer's disease;
b. determining in the patient the presence of at least one of the specific genotypes selected from the group consisting of:
i. heterozygosity for C/T for Insulin Degrading Enzyme (IDE) rs 2251101 at relevant portion shown by SEQ ID NO:3, and
ii. absence of homozygosity for C/C of IDE rs 2251101 at relevant portion shown by SEQ ID NO:3; and
administering to the patient having at least one of the specific genotypes in (b a composition comprising an effective amount of medium chain triglycerides (MCT) of the formula:
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains.
2. The method of claim 1 , wherein the method further comprises testing the patient for the absence of ApoE4 genotype.
3. The method of claim 1 , wherein the composition is an oral composition which further comprises glucose.
4. The method of claim 1 , wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.1 mM to about 50 mM.
5. The method of claim 1 , wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.2 mM to about 5 mM.
6. The method of claim 1 , wherein the composition is administered at a dose of about 0.05 g/kg/day to about 10 g/kg/day.